Skip to main content
eXit

ImmunoSensation leaves X

Due to recent developments, we decided to discontinue our activities on the social media plattform X. With this decision, we follow more than 60 german universities and other research institutions. As a Cluster of Excellence, we see the communication of research and scientific results as well as their discussion as one of our tasks, which is why we did not make this decision lightly. However, X's line is not compatible with the basic values that we represent and also want to live in our communication. These include transparency, constructive discourse and, above all, scientific integrity.

We are looking forward to welcome you on our channels at

Bluesky

LinkedIn

Instagram

facebook

youtube

 

Related news

Tracking glioblastoma cell spread in human brain tissue

Publication

Core2Edge: How tumor cells conquer the brain

—Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

Publication

Approval of a Novel Retinal Implant Technology

—A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry
Prof. Dr. Frank G. Holz – Director of the Department of Ophthalmology at the University Hospital Bonn (UKB) and Professor at the University of Bonn.

Honors & Funding

Frank Holz Nominated for the Science Breakthrough of the Year 2026

—A remarkable achievement for the Faculty of Medicine at the University of Bonn: Prof. Dr. Frank G. Holz, Director of the Department of Ophthalmology at the UKB and Professor at the University of Bonn, has been shortlisted for the Falling Walls Science Breakthrough of the Year 2026 in the Life Sciences category. His project is now among the 30 most outstanding scientific innovations worldwide in this category, recognized by the prestigious Falling Walls Science Summit. Being shortlisted alone represents a significant international distinction.
View entry

Back to the news overview